pulmonary artery hypertension
Conditions
Interventions
control :basic treatment
experimental group:tanshinone IIA sulfonic acid natrium aerosol inhalation based on routine treatment
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
16 Years to 75 Years
Inclusion criteria
Inclusion criteria: Diagnostic criteria: (1) conform to the pulmonary artery high pressure at sea level, the resting state, the right cardiac catheterization examination average pulmonary artery pressure (mPAP) 25 mm Hg or higher, and pulmonary capillary wedge pressure (PCWP) 15 MMHG or less; (2) the nice classification in 2013 patients with 1, 3, 4 class period, specific include: idiopathic pulmonary hypertension. Hereditary pulmonary hypertension; A drug or poison causes of pulmonary hypertension; Related factors caused by pulmonary hypertension [connective tissue disease, congenital heart disease (no indications/intervention or surgery/more than 6 months after intervention treatment and stable)]; Chronic obstructive pulmonary disease, interstitial lung disease, and other restrictive and obstructive airway disorders combination disease, long-term living plateau environment caused by pulmonary hypertension; Chronic thromboembolic pulmonary hypertension [with surgical indications is the preferred surgical treatment, postoperative pulmonary hypertension is still exist, or no surgical indications should be use of anticoagulant drugs (such as warfarin) stability more than 1 months]; (3) age 15 to 70 years old, men and women not limited; (4) WHO pulmonary artery II, III, IV level; (5) 6 MWDS baseline acuity 100 m and 450 m; (6) the subjects after foundation treatment in stable condition after more than 1 months, patients with congenital heart disease intervention or surgery sealing treatment for 6 months or more; (7) the participants or their guardians agree to participate in this test, and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) does not have legal capacity and legal capacity limitation; (2) during pregnancy and lactation women; (3) important organs have serious primary diseases, responsible for doctors determined doesn't fit into the group; (4) on the mental or physical disability patients, responsible for doctors determined doesn't fit into the group; (5) doubt or have alcohol and drug abuse history; (6) this medicine composition has known allergies; (7) AST, ALT 3 times more than normal ceiling, Ccr 50 ml/min or less; (8) systemic blood pressure in patients with low blood pressure ( blood pressure 170/110 MMHG); (9) for ever use targeted drug therapy and disable or change the targeted drugs less than 3 months; (10) including hepatitis a and hepatitis b, HIV/AIDS, tuberculosis and other infectious diseases, or connective tissue diseases in activity; (11) severe infections, especially lung infection; (12) shock or other hemodynamic instability; (13) cirrhosis of the liver or liver cirrhosis patients with portal hypertension causedPatients with portal hypertension; (14) for severe bleeding or bleeding tendency, such as active peptic ulcer, intracranial hemorrhage, trauma, or other bleeding; (15) and organic acute or chronic disease (except breathing difficulties) or for other reasons such as lower limbs diseases lead to cannot fulfill the study subjects need to monitor that required by the project (especially 6 min walking distance testing); (16) researchers think doesn't fit to participate in the test of any other person.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| six-minutes walking test;A second heart rate recovery; | — |
Secondary
| Measure | Time frame |
|---|---|
| pulmonary artery systolic pressure by Echocardiography;Liver Function;renal function; | — |
Countries
China
Contacts
Public ContactJian Wang
Outcome results
None listed